Farxiga vs Jardiance
At a glance
| Farxiga | Jardiance | |
|---|---|---|
| Generic name | Farxiga | Jardiance |
| Sponsor | AstraZeneca | University of Louisville |
| Molecular target | Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1 | Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2 |
| Modality | Small molecule | Small molecule |
| Phase | FDA-approved | FDA-approved |
| Therapeutic area | Metabolic | Metabolic |
Mechanism of action
| Farxiga | — |
|---|---|
| Jardiance | — |
Approved indications
Farxiga
- Chronic heart failure
- Chronic kidney disease
- Diabetes mellitus type 1
- Diabetes mellitus type 2
Jardiance
- Chronic heart failure
- Diabetes mellitus type 2
Common side effects
Farxiga
- Female genital mycotic infections
- Nasopharyngitis
- Urinary tract infections
- Back pain
- Increased urination
- Male genital mycotic infections
Jardiance
- Urinary tract infections
- Female genital mycotic infections
- Upper respiratory tract infection
- Dyslipidemia
- Increased urination
- Arthralgia
- Male genital mycotic infections
- Nausea
Further reading
- Full profile: Farxiga
- Full profile: Jardiance
- Markdown for LLMs: Farxiga.md · Jardiance.md